Topic: MS

Re-evaluating the balance of efficacy and safety with disease-modifying therapies

June 8, 2023  

Selected highlights from CMSC 2023

June 6, 2023  

NfL – a guide to use in MS practice

May 31, 2023  

AAN update on anti-CD20 agents: long-term data

May 10, 2023  

Emerging role of CHI3L1 as MS biomarker

May 2, 2023  

sNfL a biomarker of future disease activity: APLIOS

April 12, 2023  

Is vitamin D supplementation justified?

April 5, 2023  

CLINICAL CASES IN MS – A YOUNG WOMAN WITH BREAKTHROUGH DISEASE ON FINGOLIMOD

March 29, 2023  

Putting biomarkers into practice

March 8, 2023  

CNS effects of Wegovy (semaglutide)

February 28, 2023